Key Facts and Data Points

  • Scheme Name: Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)
  • Launch: Originally Jan Aushadhi Scheme in 2008; re‑branded in 2016.
  • Administered by: Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers.
  • Product Portfolio (2026): ~2,110 generic medicines & 315 surgical items across 29 therapeutic categories.
  • Price Advantage: Medicines priced 50‑80% lower than branded equivalents.
  • Quality Assurance: Procurement from WHO‑GMP certified manufacturers; testing in NABL‑accredited labs.
  • Sanitary Napkin Initiative: Oxo‑biodegradable pads at Rs 1 per pad (since 2019).
  • Digital Tool: Jan Aushadhi Sugam App – geo‑location, availability, price‑comparison.
  • Franchise Incentives: One‑time support up to Rs 2 lakh for women, SC/ST, Divyangjan, ex‑servicemen entrepreneurs.
  • Network Size (early 2026): Over 18,000 Kendras.
  • Target Expansion: 25,000 Kendras by March 2027, with focus on rural, remote, railway stations, and hospital premises.
  • Economic Impact: Estimated Rs 38,000 crore savings for citizens by June 2025.

Background and Context

The Jan Aushadhi initiative was conceived to address the high cost of branded medicines, a major component of out‑of‑pocket (OOP) health spending in India. By leveraging generic drug production, the government seeks to make essential medicines affordable, especially for the economically disadvantaged. The scheme aligns with the broader goal of Universal Health Coverage (UHC) and complements other flagship health programmes such as Ayushman Bharat.

Significance for India / Governance / Policy

  • Financial Protection: Directly reduces OOP health expenditure, mitigating the risk of catastrophic health spending.
  • Access Equity: Expands reach to remote and underserved areas through innovative Kendra locations (railway stations, PACS‑linked rural hubs).
  • Entrepreneurship & Inclusion: Franchise model promotes participation of marginalized groups, fostering inclusive economic growth.
  • Quality Assurance: Ensures that cost‑effectiveness does not compromise safety, building public trust.
  • Policy Synergy: Supports the National Health Policy 2017 goal of reducing OOP health spending to <30% of total health expenditure.

Related Constitutional / Legal Provisions

  • Article 21 (Right to Life): Indian jurisprudence interprets the right to life to include the right to health; affordable medicines are integral to this right.
  • National Pharmaceutical Pricing Authority (NPPA) Act, 1998: Provides regulatory framework for price control of essential medicines, complementing the generic supply model of PMBJP.
  • The Drugs and Cosmetics Act, 1940: Governs quality standards; PMBJP’s adherence to WHO‑GMP and NABL aligns with statutory requirements.

References for Further Study

  • Ministry of Chemicals & Fertilizers – Annual Report 2025‑26.
  • National Health Policy 2017.
  • Ayushman Bharat – Health and Wellness Centres.
  • Supreme Court judgments on the right to health (e.g., Paschim Banga Khet Mazdoor Samiti v. State of West Bengal).